Evidence map›Paper›PMID 35665305›Full record

ArticleHepatic oncology2022

Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma.

Ellery Altshuler, Mahmoud Aryan, Govind Kallumkal, Hanzhi Gao, Jake Wilson, Ahmed Ouni, Edward De Leo, Wissam Hanayneh, Kelsey Pan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ellery AltshulerDepartment of Internal Medicine, University of Florida College of Medicine, Gainesville, FL, USA.ORCID https://orcid.org/0000-0003-1811-317X
Mahmoud AryanDepartment of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Govind KallumkalDepartment of Internal Medicine, University of Florida College of Medicine, Gainesville, FL, USA.
Hanzhi GaoDepartment of Biostatistics, University of Florida, Gainesville, FL, USA.
Jake WilsonDepartment of Internal Medicine, University of Florida College of Medicine, Gainesville, FL, USA.
Ahmed OuniDepartment of Gastroenterology, Mayo Clinic, Jacksonville, FL, USA.
Edward De LeoDepartment of Internal Medicine, University of Florida College of Medicine, Gainesville, FL, USA.
Wissam HanaynehDivision of Medical Oncology, H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
Kelsey PanDepartment of Internal Medicine, University of Florida College of Medicine, Gainesville, FL, USA.
University of Florida · USWinnMed · USUniversity of Alabama at Birmingham · USUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: β-blockers (BBs) have shown promise in improving overall survival (OS) in patients with breast, ovarian, pancreatic and lung cancer. However, few studies have evaluated the impact of BBs on unresectable hepatocellular carcinoma (HCC). Methods: The authors compared clinical data and outcomes between unresectable HCC patients based on whether they were prescribed BBs. Results: There was significantly decreased disease progression in the BB group compared with the non-BB group (22.8 vs 28.0%; p < 0.05). No difference was seen in OS or progression-free survival between groups. Those specifically on selective BBs had improved OS (hazard ratio: 0.75; 95% CI: 0.61-0.94; p = 0.01) and progression-free survival (hazard ratio: 0.66; 95% CI: 0.45-0.96; p = 0.03) compared with non-BB patients. Conclusion: Although the authors' study did not demonstrate that BBs improve OS in HCC, it did show decreased disease progression among patients with HCC who were taking BBs compared with those who were not.

Indexed as

hepatocellular carcinomaunresectableβ-blockers

Identifiers

PMID35665305
PMCPMC9136628
OpenAlexW4281396830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.